Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

NCT05320159 COMPLETED

This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.

Details

Lead sponsor	Novartis Pharmaceuticals
Status	COMPLETED
Enrolment	17743
Start date	Wed Feb 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Psoriasis

Interventions

• Secukinumab

Countries

United States